Powder: -20°C for 3 years
In solvent: -80°C for 2 years
UCM-1306 is a potent and orally active allosteric modulator (PAM) of human dopamine D1 receptor. UCM-1306 could increase the maximal effect of endogenous dopamine (DA) both in human and mouse D1 receptors. UCM-1306 could improve motor symptoms and address the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD).
Description | UCM-1306 is a potent and orally active allosteric modulator (PAM) of human dopamine D1 receptor. UCM-1306 could increase the maximal effect of endogenous dopamine (DA) both in human and mouse D1 receptors. UCM-1306 could improve motor symptoms and address the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD). |
In vitro | UCM-1306 (1-10 μM) enhances CAMP in a concentration-response manner, EC50=60 nM[1]. |
In vivo | UCM-1306 (p.o.; C57BL/6J mice) has good brain penetration and oral availability. The plasma concentration can be quantified within 8 hours, and Tmax is 0.5 hours. UCM-1306 (1 mg/kg; ip) enhances cocaine induced hyperactivity in adult mice. UCM-1306 (1 mg/kg; ip) helps to consolidate the formation of long-term memory [1]. |
Molecular Weight | 279.33 |
Formula | C14H14FNO2S |
CAS No. | 2258608-78-3 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 45.0 mg/mL (161.1 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UCM-1306 2258608-78-3 GPCR/G Protein Neuroscience Dopamine Receptor UCM1036 Inhibitor inhibitor inhibit